The popularity of Viagra initially drove a boom for major pharmaceutical companies, but recent changes present a uncertain scenario for those considering a stake. Off-patent versions are eating into revenue, and continued litigation add further risk to the situation. While some companies might still see gains from adjacent offerings, the general tr